Premium
Two cases of burning mouth syndrome treated with olanzapine
Author(s) -
Ueda Nobuhisa,
Kodama Yuki,
Hori Hikaru,
Umene Wakako,
Sugita Atsuko,
Nakano Hideki,
Yoshimura Reiji,
Nakamura Jun
Publication year - 2008
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.2008.01806.x
Subject(s) - olanzapine , milnacipran , paroxetine , medicine , anesthesia , regimen , pediatrics , surgery , psychiatry , schizophrenia (object oriented programming) , antidepressant , anxiety
Two case reports of patients suffering from burning mouth syndrome (BMS), a type of somatoform disorder, who were treated with olanzapine are discussed. One case was a 54‐year‐old female with BMS who failed to respond to milnacipran treatment. Olanzapine (2.5 mg/day) brought about dramatic improvement in the patient's symptoms, and thereafter milnacipran withdrawal further eliminated her symptoms. The second case was a 51‐year‐old male with BMS who failed to respond to paroxetine treatment. Olanzapine (2.5 mg/day) was added to the treatment regimen and increased to 5.0 mg/day the following week. The patient noted a reduction in symptoms and continued to live normally thereafter without experiencing severe symptoms. These findings suggest that olanzapine may be useful in the treatment of BMS.